首页> 外文OA文献 >Systematic Literature Review (SLR) Of Health State Utility Values (HSUV) In Epidermal Growth Factor Receptor Mutant (Egfr-Mutant) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated With Targeted Therapies

【2h】

Systematic Literature Review (SLR) Of Health State Utility Values (HSUV) In Epidermal Growth Factor Receptor Mutant (Egfr-Mutant) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated With Targeted Therapies

机译：表皮生长因子受体突变体（EGFR-突变体）非小细胞肺癌（NSCLC）患者的健康状态效用值（HSUV）的系统文献综述（SLR）患者以前用靶向疗法治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
A Shor; A Forsythe; S Li; A Galaznik;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第2016期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
2. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第4期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
3. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial) [J] . Kazuhiro Usui Takuma Yokoyama, Go Naka, Hiroo Ishida, Japanese journal of clinical oncology. . 2019,第6期

机译：表皮生长因子受体（EGFR）中的血浆CTDNA监测 - 富集突变体非小细胞肺癌（JP-CLEAR试验）患者中的幼粒激酶抑制剂治疗
4. Development and validation of a radiomics nomogram for progression-free survival prediction in stage IV EGFR-mutant non-small cell lung cancer [C] . Jiangdian Song, Yali Zang, Weimin Li, Conference on Computer-Aided Diagnosis . 2017

机译：放射组学诺模图的开发和验证，用于IV期EGFR突变非小细胞肺癌的无进展生存期预测
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [O] . Yu-Mu Chen, Chien-Hao Lai, Huang-Chih Chang, -1

机译：一线表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变型非小细胞肺癌患者的淋巴细胞与单核细胞比率的基线和趋势作为预后因素
7. Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. [O] . Yu-Mu Chen, Chien-Hao Lai, Huang-Chih Chang, 2015

机译：淋巴细胞与单核细胞比率的基线和趋势作为表皮生长因子受体突变非小细胞肺癌患者用一线表皮生长因子受体酪氨酸激酶抑制剂治疗的预后因素。

Systematic Literature Review (SLR) Of Health State Utility Values (HSUV) In Epidermal Growth Factor Receptor Mutant (Egfr-Mutant) Non-Small Cell Lung Cancer (NSCLC) Patients Previously Treated With Targeted Therapies

著录项

引文网络

相似文献

相关主题

期刊订阅